SUPPLEMENT

Q3 2025 — Financial disclosures

Q3 2025PDF · 10 pages1.3 MB
Merck & Co., Inc.,
Rahway, N.J., USA
Financial Highlights Package
Third Quarter 2025
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 3Q25 and Sept YTD 25.......3
Table 2b: GAAP to Non-GAAP Reconciliation 3Q24 and Sept YTD 24.......4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / International 3Q25.................................................6
Table 3b: Sales – U.S. / International Sept YTD 25.....................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	17,276	$ 	16,657	$ 	4% 	48,611	$ 	48,544	$ 	0%
Costs, Expenses and Other
Cost of sales 	3,855 	4,080 	-6% 	10,831 	11,365 	-5%
Selling, general and administrative 	2,633 	2,731 	-4% 	7,835 	7,952 	-1%
Research and development 	4,234 	5,862 	-28% 	11,903 	13,354 	-11%
Restructuring costs 	47 	56 	-16% 	676 	258 	*
Other (income) expense, net 	(238) 	(162) 	47% 	(281) 	(151) 	86%
Income Before Taxes 	6,745 	4,090 	65% 	17,647 	15,766 	12%
Income Tax Provision 	958 	929 	2,346 	2,377
Net Income 	5,787 	3,161 	83% 	15,301 	13,389 	14%
Less: Net Income Attributable to Noncontrolling Interests 	2 	4 	10 	15
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	5,785	$ 	3,157	$ 	83% 	15,291	$ 	13,374	$ 	14%
Earnings per Common Share Assuming Dilution 	2.32	$ 	1.24	$ 	87% 	6.08	$ 	5.26	$ 	16%
Average Shares Outstanding Assuming Dilution 	2,498 	2,541 	2,514 	2,543
Tax Rate 	14.2% 	22.7% 	13.3% 	15.1%
* 100% or greater
GAAP
% Change
3Q25 	3Q24
GAAP
% Change	Sep YTD
2025
Sep YTD
2024
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
1

-- 2 of 10 --

Sales 	15,529	$ 	15,806	$ 	17,276	$ 	48,611	$ 	15,775	$ 	16,112	$ 	16,657	$ 	48,544	$ 	15,624	$ 	64,168	$ 	4% 	0%
Costs, Expenses and Other
Cost of sales 	3,419 	3,557 	3,855 	10,831 	3,540 	3,745 	4,080 	11,365 	3,828 	15,193 	-6% 	-5%
Selling, general and administrative 	2,552 	2,649 	2,633 	7,835 	2,483 	2,739 	2,731 	7,952 	2,864 	10,816 	-4% 	-1%
Research and development 	3,621 	4,048 	4,234 	11,903 	3,992 	3,500 	5,862 	13,354 	4,585 	17,938 	-28% 	-11%
Restructuring costs 	69 	560 	47 	676 	123 	80 	56 	258 	51 	309 	-16% 	*
Other (income) expense, net 	(35) 	(7) 	(238) 	(281) 	(33) 	42 	(162) 	(151) 	126 	(24) 	47% 	86%
Income Before Taxes 	5,903 	4,999 	6,745 	17,647 	5,670 	6,006 	4,090 	15,766 	4,170 	19,936 	65% 	12%
Income Tax Provision 	818 	571 	958 	2,346 	903 	545 	929 	2,377 	425 	2,803
Net Income 	5,085 	4,428 	5,787 	15,301 	4,767 	5,461 	3,161 	13,389 	3,745 	17,133 	83% 	14%
Less: Net Income Attributable to Noncontrolling Interests 	6 	1 	2 	10 	5 	6 	4 	15 	2 	16
Net Income Attributable to Merck & Co., Inc., Rahway, N.J.,
USA
5,079	$ 	4,427	$ 	5,785	$ 	15,291	$ 	4,762	$ 	5,455	$ 	3,157	$ 	13,374	$ 	3,743	$ 	17,117	$ 	83% 	14%
Earnings per Common Share Assuming Dilution 	2.01	$ 	1.76	$ 	2.32	$ 	6.08	$ 	1.87	$ 	2.14	$ 	1.24	$ 	5.26	$ 	1.48	$ 	6.74	$ 	87% 	16%
Average Shares Outstanding Assuming Dilution 	2,531 	2,513 	2,498 	2,514 	2,544 	2,544 	2,541 	2,543 	2,537 	2,541
Tax Rate 	13.9% 	11.4% 	14.2% 	13.3% 	15.9% 	9.1% 	22.7% 	15.1% 	10.2% 	14.1%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
Full Year
2025
2Q 	3Q 	Sep YTD	1Q 	1Q 	2Q 	3Q
2024
4Q 	3Q 	Sep YTD
% Change
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
Sep YTD
2

-- 3 of 10 --

Third Quarter
Cost of sales 	3,855	$ 	621 	110 	731 	3,124	$
Selling, general and administrative 	2,633 	34 	34 	2,599
Research and development 	4,234 	4 	233 	237 	3,997
Restructuring costs 	47 	47 	47 	–
Other (income) expense, net 	(238) 	(344) 	(344) 	106
Income Before Taxes 	6,745 	(659) 	(390) 	344 	(705) 	7,450
Income Tax Provision (Benefit) 	958 	(119) (3) 	(82) (3) 	73 (3) 	86 (4) 	(42) 	1,000
Net Income 	5,787 	(540) 	(308) 	271 	(86) 	(663) 	6,450
Net Income Attributable to Merck & Co., Inc., Rahway, N.J.,
USA 	5,785 	(540) 	(308) 	271 	(86) 	(663) 	6,448
Earnings per Common Share Assuming Dilution 	2.32	$ 	(0.22) 	(0.12) 	0.11 	(0.03) 	(0.26) 	2.58	$
Tax Rate 	14.2% 	13.4%
Sep YTD
Cost of sales 	10,831	$ 	1,817 	311 	2,128 	8,703	$
Selling, general and administrative 	7,835 	72 	1 	73 	7,762
Research and development 	11,903 	14 	286 	300 	11,603
Restructuring costs 	676 	676 	676 	–
Other (income) expense, net 	(281) 	(3) 	(512) 	(515) 	234
Income Before Taxes 	17,647 	(1,900) 	(1,274) 	512 	(2,662) 	20,309
Income Tax Provision (Benefit) 	2,346 	(338) (3) 	(239) (3) 	109 (3) 	(60) (4) 	(528) 	2,874
Net Income 	15,301 	(1,562) 	(1,035) 	403 	60 	(2,134) 	17,435
Net Income Attributable to Merck & Co., Inc., Rahway, N.J.,
USA 	15,291 	(1,562) 	(1,035) 	403 	60 	(2,134) 	17,425
Earnings per Common Share Assuming Dilution 	6.08	$ 	(0.62) 	(0.41) 	0.16 	0.02 	(0.85) 	6.93	$
Tax Rate 	13.3% 	14.2%
Only the line items that are affected by non-GAAP adjustments are shown.
GAAP
Acquisition- and
Divestiture-Related Costs	
(1)	
Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Adjustment
Subtotal 	Non-GAAP	Certain Other Items
MERCK & CO., INC., RAHWAY, N.J., USA
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures
internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in
part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales for the third quarter reflect expenses for the amortization of intangible assets. Amounts included in cost of sales for the nine-month period include the amortization of intangible assets and
intangible asset impairment charges, partially offset by a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in selling, general and administrative expenses reflect
integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested, and contractual termination costs related to activities under the
Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Amount in the third quarter represents tax expense relating to audit reserve adjustments. Amount in the nine-month period represents a tax benefit, including a net benefit related to favorable audit reserve adjustments.
3

-- 4 of 10 --

Third Quarter
Cost of sales 	4,080	$ 	639 	192 	831 	3,249	$
Selling, general and administrative 	2,731 	43 	31 	74 	2,657
Research and development 	5,862 	24 	24 	5,838
Restructuring costs 	56 	56 	56 	–
Other (income) expense, net 	(162) 	(27) 	58 	31 	(193)
Income Before Taxes 	4,090 	(679) 	(279) 	(58) 	(1,016) 	5,106
Income Tax Provision (Benefit) 	929 	(129) (3) 	(46) (3) 	(13) (3) 	(188) 	1,117
Net Income 	3,161 	(550) 	(233) 	(45) 	(828) 	3,989
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	3,157 	(550) 	(233) 	(45) 	(828) 	3,985
Earnings per Common Share Assuming Dilution 	1.24	$ 	(0.22) 	(0.09) 	(0.02) 	(0.33) 	1.57	$
Tax Rate 	22.7% 	21.9%
Sep YTD
Cost of sales 	11,365	$ 	1,708 	374 	2,082 	9,283	$
Selling, general and administrative 	7,952 	88 	67 	155 	7,797
Research and development 	13,354 	60 	2 	62 	13,292
Restructuring costs 	258 	258 	258 	–
Other (income) expense, net 	(151) 	(48) 	(107) 	(155) 	4
Income Before Taxes 	15,766 	(1,808) 	(701) 	107 	(2,402) 	18,168
Income Tax Provision (Benefit) 	2,377 	(350) (3) 	(118) (3) 	23 (3) 	(259) (4) 	(704) 	3,081
Net Income 	13,389 	(1,458) 	(583) 	84 	259 	(1,698) 	15,087
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	13,374 	(1,458) 	(583) 	84 	259 	(1,698) 	15,072
Earnings per Common Share Assuming Dilution 	5.26	$ 	(0.57) 	(0.23) 	0.03 	0.10 	(0.67) 	5.93	$
Tax Rate 	15.1% 	17.0%
Only the line items that are affected by non-GAAP adjustments are shown.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
MERCK & CO., INC., RAHWAY, N.J., USA
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
Non-GAAP	Certain Other Items 	Adjustment Subtotal
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-
GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to
measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information
presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and
divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets and Animal Health intangible asset impairment charges. Amounts included in other (income) expense, net, primarily reflect royalty
income related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.
4

-- 5 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2025 	2024 	3Q 	Sep YTD
1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q 	3Q 	Sep YTD 	4Q 	Full Year 	Nom % Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$15,529 $15,806 $17,276 $48,611 	$15,775 	$16,112 $16,657 $48,544 $15,624 $64,168 	4 	3 	0 	1
PHARMACEUTICAL 	13,638 	14,050 	15,611 	43,299 	14,006 	14,408 	14,943 	43,358 	14,042 	57,400 	4 	3 	0 	0
Oncology
Keytruda 	7,205 	7,956 	8,142 	23,303 	6,947 	7,270 	7,429 	21,646 	7,836 	29,482 	10 	8 	8 	8
Alliance Revenue – Lynparza (2) 	312 	370 	379 	1,061 	292 	317 	337 	947 	365 	1,311 	12 	12 	12 	12
Alliance Revenue – Lenvima (2) 	258 	265 	258 	781 	255 	249 	251 	755 	255 	1,010 	3 	2 	3 	3
Welireg 	137 	162 	196 	496 	85 	126 	139 	349 	160 	509 	42 	41 	42 	42
Alliance Revenue – Reblozyl (3) 	119 	107 	136 	361 	71 	90 	100 	261 	110 	371 	36 	36 	39 	39
Vaccines (4)
Gardasil/Gardasil 9 	1,327 	1,126 	1,749 	4,202 	2,249 	2,478 	2,306 	7,032 	1,550 	8,583 	-24 	-25 	-40 	-40
ProQuad/M-M-R II/Varivax 	539 	609 	684 	1,832 	570 	617 	703 	1,891 	594 	2,485 	-3 	-3 	-3 	-3
Vaxneuvance 	230 	229 	226 	685 	219 	189 	239 	647 	161 	808 	-6 	-7 	6 	6
RotaTeq 	228 	121 	204 	554 	216 	163 	193 	572 	139 	711 	6 	5 	-3 	-3
Capvaxive 	107 	129 	244 	480 	47 	47 	50 	97 	* 	* 	* 	*
Pneumovax 23 	41 	38 	45 	124 	61 	59 	68 	188 	74 	263 	-34 	-35 	-34 	-34
Hospital Acute Care
Bridion 	441 	461 	439 	1,341 	440 	455 	420 	1,315 	449 	1,764 	5 	4 	2 	2
Prevymis 	208 	228 	266 	702 	174 	188 	208 	570 	215 	785 	28 	25 	23 	23
Zerbaxa 	70 	74 	81 	225 	56 	62 	64 	182 	70 	252 	25 	24 	24 	24
Dificid 	83 	96 	43 	222 	73 	92 	96 	261 	79 	340 	-55 	-55 	-15 	-15
Cardiovascular
Winrevair 	280 	336 	360 	976 	70 	149 	219 	200 	419 	141 	141 	* 	*
Alliance Revenue - Adempas/Verquvo (5) 	106 	123 	112 	340 	98 	106 	102 	306 	109 	415 	9 	9 	11 	11
Adempas (6) 	68 	80 	82 	229 	70 	72 	72 	214 	73 	287 	14 	7 	7 	5
Virology
Lagevrio 	102 	83 	138 	323 	350 	110 	383 	843 	121 	964 	-64 	-65 	-62 	-62
Isentress/Isentress HD 	90 	86 	82 	258 	111 	89 	102 	302 	92 	394 	-20 	-21 	-15 	-14
Delstrigo 	67 	83 	77 	228 	56 	60 	65 	180 	69 	249 	19 	13 	26 	24
Pifeltro 	45 	41 	43 	128 	42 	39 	42 	123 	40 	163 	1 	-1 	4 	4
Neuroscience
Belsomra 	50 	40 	47 	137 	46 	53 	78 	177 	45 	222 	-40 	-40 	-23 	-22
Immunology
Simponi 	184 	172 	189 	545 	543 	-100 	-100 	-100 	-100
Remicade 	39 	35 	41 	115 	114 	-100 	-100 	-100 	-100
Diabetes (7)
Januvia 	549 	372 	382 	1,302 	419 	405 	278 	1,102 	232 	1,334 	37 	37 	18 	19
Janumet 	247 	251 	243 	741 	251 	224 	204 	679 	255 	935 	19 	20 	9 	11
Other Pharmaceutical (8) 	729 	584 	953 	2,268 	632 	618 	638 	1,890 	699 	2,590 	50 	49 	20 	21
ANIMAL HEALTH 	1,588 	1,646 	1,615 	4,849 	1,511 	1,482 	1,487 	4,480 	1,397 	5,877 	9 	7 	8 	10
Livestock 	924 	961 	1,023 	2,909 	850 	837 	886 	2,573 	889 	3,462 	16 	14 	13 	15
Companion Animal 	664 	685 	592 	1,940 	661 	645 	601 	1,907 	508 	2,415 	-2 	-3 	2 	2
Other Revenues (9) 	303 	110 	50 	463 	258 	222 	227 	706 	185 	891 	-78 	-27 	-34 	-4
*200% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Total Diabetes sales were $876 million, $704 million and $703 million in the first, second and third quarter of 2025, respectively, and $745 million, $715 million and $592 million in the first, second
and third quarter of 2024.
(8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $44 million, $43 million and $214 million in the first, second and third quarter of
2025, respectively, and $38 million, $37 million and $39 million in the first, second and third quarter of 2024, respectively.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues
related to the receipt of upfront and milestone payments for out-licensed products were $95 million, $5 million and $11 million in the first, second and third quarter of 2025, respectively, and $61
million, $15 million and $15 million in the first, second and third quarter of 2024, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.	
(4) Total Vaccines sales were $2,607 million, $2,370 million and $3,370 million in the first, second and third quarter of 2025, respectively, and $3,424 million, $3,656 million and $3,675 million in the
first, second and third quarter of 2024, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.	
(6) Net product sales in the Company's marketing territories.
5

-- 6 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
THIRD QUARTER 2025
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
3Q 2025 3Q 2024 % Change 	3Q 2025 	3Q 2024 % Change 	3Q 2025 3Q 2024 % Change
TOTAL SALES (1) 	$17,276 	$16,657 	4 	$10,012 	$8,736 	15 	$7,264 	$7,922 	-8
PHARMACEUTICAL 	15,611 	14,943 	4 	9,493 	8,227 	15 	6,118 	6,717 	-9
Oncology
Keytruda 	8,142 	7,429 	10 	4,879 	4,500 	8 	3,263 	2,929 	11
Alliance Revenue – Lynparza (2) 	379 	337 	12 	184 	161 	14 	195 	177 	11
Alliance Revenue – Lenvima (2) 	258 	251 	3 	177 	173 	2 	81 	78 	4
Welireg 	196 	139 	42 	161 	127 	27 	35 	12 	196
Alliance Revenue – Reblozyl (3) 	136 	100 	36 	111 	82 	35 	25 	18 	40
Vaccines (4)
Gardasil/Gardasil 9 	1,749 	2,306 	-24 	1,154 	1,020 	13 	595 	1,285 	-54
ProQuad/M-M-R II/Varivax 	684 	703 	-3 	554 	572 	-3 	130 	131 	-1
Capvaxive 	244 	47 	* 	238 	47 	* 	7 	0 	*
Vaxneuvance 	226 	239 	-6 	134 	137 	-1 	91 	103 	-11
RotaTeq 	204 	193 	6 	141 	131 	8 	63 	62 	2
Pneumovax 23 	45 	68 	-34 	10 	19 	-48 	35 	49 	-28
Hospital Acute Care
Bridion 	439 	420 	5 	392 	339 	15 	47 	81 	-42
Prevymis 	266 	208 	28 	128 	101 	27 	138 	107 	29
Zerbaxa 	81 	64 	25 	49 	39 	25 	32 	26 	25
Dificid 	43 	96 	-55 	30 	83 	-64 	13 	13 	-2
Cardiovascular
Winrevair 	360 	149 	141 	335 	147 	129 	25 	3 	*
Alliance Revenue - Adempas/Verquvo (5)	
112 	102 	9 	103 	96 	8 	8 	7 	25
Adempas (6)	
82 	72 	14 	82 	72 	14
Virology
Lagevrio 	138 	383 	-64 	24 	84 	-71 	114 	299 	-62
Isentress/Isentress HD 	82 	102 	-20 	44 	54 	-18 	37 	48 	-23
Delstrigo 	77 	65 	19 	13 	15 	-13 	64 	50 	29
Pifeltro 	43 	42 	1 	29 	31 	-7 	14 	12 	21
Neuroscience
Belsomra 	47 	78 	-40 	28 	20 	40 	19 	58 	-67
Immunology
Simponi 	189 	-100 	189 	-100
Remicade 	41 	-100 	41 	-100
Diabetes (7)
Januvia 	382 	278 	37 	258 	67 	* 	124 	211 	-42
Janumet 	243 	204 	19 	78 	15 	* 	165 	190 	-13
Other Pharmaceutical (8) 	953 	638 	50 	239 	167 	43 	716 	466 	54
ANIMAL HEALTH 	1,615 	1,487 	9 	504 	487 	3 	1,112 	999 	11
Livestock 	1,023 	886 	16 	213 	194 	10 	811 	692 	17
Companion Animal 	592 	601 	-2 	291 	293 	-1 	301 	307 	-2
Other Revenues (9) 	50 	227 	-78 	15 	22 	-32 	34 	206 	-83
*200% or greater
(6) Net product sales in the Company's marketing territories.
(7) Total Diabetes sales were $703 million and $592 million on a global basis in the third quarter of 2025 and 2024, respectively.
(8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $214 million and $39 million on a global basis in
the third quarter of 2025 and 2024, respectively.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $11
million and $15 million in the third quarter of 2025 and 2024, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $3,370 million and $3,675 million on a global basis in the third quarter of 2025 and 2024, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs.
6

-- 7 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
SEPTEMBER YEAR-TO-DATE 2025
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
Sep YTD 2025 Sep YTD 2024 % Change 	Sep YTD 2025
Sep YTD
2024 	% Change
Sep YTD
2025
Sep YTD
2024 	% Change
TOTAL SALES (1) 	$48,611 	$48,544 	0 	$27,371 $24,089 	14 	$21,240 	$24,455 	-13
PHARMACEUTICAL 	43,299 	43,358 	0 	25,747 	22,563 	14 	17,552 	20,795 	-16
Oncology
Keytruda 	23,303 	21,646 	8 	13,936 	13,031 	7 	9,367 	8,614 	9
Alliance Revenue – Lynparza (2) 	1,061 	947 	12 	503 	449 	12 	558 	498 	12
Alliance Revenue – Lenvima (2) 	781 	755 	3 	545 	523 	4 	236 	233 	2
Welireg 	496 	349 	42 	422 	320 	32 	74 	29 	157
Alliance Revenue – Reblozyl (3) 	361 	261 	39 	299 	215 	39 	62 	45 	37
Vaccines (4)
Gardasil/Gardasil 9 	4,202 	7,032 	-40 	2,235 	2,045 	9 	1,967 	4,988 	-61
ProQuad/M-M-R II/Varivax 	1,832 	1,891 	-3 	1,457 	1,500 	-3 	374 	391 	-4
Vaxneuvance 	685 	647 	6 	409 	397 	3 	276 	251 	10
RotaTeq 	554 	572 	-3 	366 	388 	-6 	187 	185 	2
Capvaxive 	480 	47 	* 	473 	47 	* 	8 	0 	*
Pneumovax 23 	124 	188 	-34 	13 	36 	-63 	111 	152 	-27
Hospital Acute Care
Bridion 	1,341 	1,315 	2 	1,181 	1,020 	16 	161 	296 	-46
Prevymis 	702 	570 	23 	345 	265 	30 	357 	305 	17
Zerbaxa 	225 	182 	24 	136 	106 	29 	89 	77 	16
Dificid 	222 	261 	-15 	185 	231 	-20 	37 	30 	21
Cardiovascular
Winrevair 	976 	219 	* 	926 	216 	* 	49 	3 	*
Alliance Revenue - Adempas/Verquvo (5)	
340 	306 	11 	308 	283 	9 	32 	22 	43
Adempas (6)	
229 	214 	7 	229 	214 	7
Virology
Lagevrio 	323 	843 	-62 	90 	144 	-38 	233 	699 	-67
Isentress/Isentress HD 	258 	302 	-15 	144 	147 	-2 	114 	155 	-26
Delstrigo 	228 	180 	26 	42 	42 	1 	185 	139 	33
Pifeltro 	128 	123 	4 	86 	86 	-1 	43 	37 	16
Neuroscience
Belsomra 	137 	177 	-23 	59 	53 	12 	77 	124 	-38
Immunology
Simponi 	545 	-100 	545 	-100
Remicade 	115 	-100 	115 	-100
Diabetes (7)
Januvia 	1,302 	1,102 	18 	819 	428 	91 	483 	674 	-28
Janumet 	741 	679 	9 	210 	70 	* 	530 	610 	-13
Other Pharmaceutical (8) 	2,268 	1,890 	20 	558 	521 	7 	1,713 	1,364 	26
ANIMAL HEALTH 	4,849 	4,480 	8 	1,505 	1,417 	6 	3,345 	3,063 	9
Livestock 	2,909 	2,573 	13 	598 	529 	13 	2,312 	2,044 	13
Companion Animal 	1,940 	1,907 	2 	907 	888 	2 	1,033 	1,019 	1
Other Revenues (9) 	463 	706 	-34 	119 	109 	9 	343 	597 	-43
*200% or greater
(6) Net product sales in the Company's marketing territories.
(7) Total Diabetes sales were $2,283 million and $2,053 million on a global basis for September YTD 2025 and 2024, respectively.
(8) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $301 million and $114 million on a global basis for
September YTD 2025 and 2024, respectively.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including
revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $111 million and $91
million on a global basis for September YTD 2025 and 2024, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $8,347 million and $10,755 million on a global basis for September YTD 2025 and 2024, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
7

-- 8 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2025 	2024 	% Change
1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q 	3Q 	Sep YTD 	4Q 	Full Year 	3Q 	Sep YTD
TOTAL PHARMACEUTICAL 	$13,638 	$14,050 	$15,611 	$43,299 	$14,006 	$14,408 	$14,943 	$43,358 	$14,042 	$57,400 	4 	0
United States 	7,927 	8,328 	9,493 	25,747 	6,936 	7,399 	8,227 	22,563 	7,728 	30,290 	15 	14
% Pharmaceutical Sales 	58.1% 	59.3% 	60.8% 	59.5% 	49.5% 	51.4% 	55.1% 	52.0% 	55.0% 	52.8%
Europe (1) 	2,384 	2,551 	2,675 	7,610 	2,555 	2,572 	2,620 	7,748 	2,498 	10,246 	2 	-2
% Pharmaceutical Sales 	17.5% 	18.2% 	17.1% 	17.6% 	18.2% 	17.9% 	17.5% 	17.9% 	17.8% 	17.9%
Japan 	651 	604 	693 	1,948 	802 	664 	919 	2,386 	813 	3,199 	-25 	-18
% Pharmaceutical Sales 	4.8% 	4.3% 	4.4% 	4.5% 	5.7% 	4.6% 	6.2% 	5.5% 	5.8% 	5.6%
Latin America 	589 	654 	691 	1,933 	601 	661 	730 	1,992 	680 	2,672 	-5 	-3
% Pharmaceutical Sales 	4.3% 	4.7% 	4.4% 	4.5% 	4.3% 	4.6% 	4.9% 	4.6% 	4.8% 	4.7%
Asia Pacific (other than China and Japan) 	535 	609 	593 	1,736 	580 	595 	669 	1,844 	612 	2,457 	-11 	-6
% Pharmaceutical Sales 	3.9% 	4.3% 	3.8% 	4.0% 	4.1% 	4.1% 	4.5% 	4.3% 	4.4% 	4.3%
China (2) 	668 	407 	377 	1,452 	1,744 	1,790 	996 	4,530 	864 	5,394 	-62 	-68
% Pharmaceutical Sales 	4.9% 	2.9% 	2.4% 	3.4% 	12.5% 	12.4% 	6.7% 	10.4% 	6.2% 	9.4%
Eastern Europe/Middle East/Africa 	435 	451 	365 	1,250 	395 	353 	400 	1,147 	348 	1,495 	-9 	9
% Pharmaceutical Sales 	3.2% 	3.2% 	2.3% 	2.9% 	2.8% 	2.4% 	2.7% 	2.6% 	2.5% 	2.6%
Canada 	125 	135 	134 	394 	138 	143 	133 	414 	144 	558 	1 	-5
% Pharmaceutical Sales 	0.9% 	1.0% 	0.9% 	0.9% 	1.0% 	1.0% 	0.9% 	1.0% 	1.0% 	1.0%
Other 	324 	311 	590 	1,229 	255 	231 	249 	734 	355 	1,089 	137 	67
% Pharmaceutical Sales 	2.4% 	2.1% 	3.9% 	2.7% 	1.9% 	1.6% 	1.5% 	1.7% 	2.5% 	1.7%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
(2) Gardasil/Gardasil 9 sales in China were $193 million, $0 and $0 in the first, second and third quarter of 2025, respectively, and $1,253 million, $1,312 million, $517 million and $446 million in the first,
second, third and fourth quarter of 2024, respectively.
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
3Q25 	3Q24
Sep YTD
2025
Sep YTD
2024
Interest income 	(96)	$ 	(127)	$ 	(274)	$ 	(269)	$
Interest expense 	327 	330 	946 	943
Exchange losses 	56 	33 	224 	177
(Income) loss from investments in equity securities, net (1) (373) 	31 	(563) 	(169)
Net periodic defined benefit plan (credit) cost other than service cost 	(152) 	(157) 	(452) 	(476)
Other, net 	- 	(272) 	(162) 	(357)
Total 	(238)	$ 	(162)	$ 	(281)	$ 	(151)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment
funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership
interests in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC., RAHWAY, N.J., USA
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --